This content is in French.
In vivo CAR-T: immunotherapy without the lab
4 mars 2026
By Ana Espino | Published on March 4, 2026 | 3 min readCAR-T cell therapy has transformed the management of certain hematologic malignancies. Traditionally, however, its development relies on a complex procedure: harvesting a patient’s T lymphocytes, genetically modifying them in the laboratory, expanding the cells, and reinfusing them. This lengthy, costly, and technically demanding process limit
By Ana Espino | Published on March 4, 2026 | 3 min read
CAR-T cell therapy has transformed the management of certain hematologic malignancies. Traditionally, however, its development relies on a complex procedure: harvesting a patient’s T lymphocytes, genetically modifying them in the laboratory, expanding the cells, and reinfusing them. This lengthy, costly, and technically demanding process limits access to treatment and creates major logistical constraints. In this context, direct in vivo generation of CAR-T cells—without ex vivo manipulation—emerges as an innovative strategy that could reshape cellular immunotherapy.
CAR-T cell therapy has transformed the management of certain hematologic malignancies. Traditionally, however, its development relies on a complex procedure: harvesting a patient’s T lymphocytes, genetically modifying them in the laboratory, expanding the cells, and reinfusing them. This lengthy, costly, and technically demanding process limits access to treatment and creates major logistical constraints. In this context, direct in vivo generation of CAR-T cells—without ex vivo manipulation—emerges as an innovative strategy that could reshape cellular immunotherapy.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Huang Y, et al. In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy. Hum Vaccin Immunother. 2025 Dec;21(1):2558403. doi: 10.1080/21645515.2025.2558403. Epub 2025 Sep 11.
View the source
